These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36341335)

  • 1. Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
    Ma YX; Liu FR; Zhang Y; Chen Q; Chen ZQ; Liu QW; Huang Y; Yang YP; Fang WF; Xi N; Kang N; Zhuang YL; Zhang Q; Jiang YZ; Zhang L; Zhao HY
    Front Immunol; 2022; 13():1024755. PubMed ID: 36341335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
    Kollmannsberger C; Hurwitz H; Bazhenova L; Cho BC; Hong D; Park K; Reckamp KL; Sharma S; Der-Torossian H; Christensen JG; Faltaos D; Potvin D; Tassell V; Chao R; Shapiro GI
    Target Oncol; 2023 Jan; 18(1):105-118. PubMed ID: 36459255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.
    Hu X; Zheng X; Yang S; Wang L; Hao X; Cui X; Ding L; Mao L; Hu P; Shi Y
    J Hematol Oncol; 2020 Jan; 13(1):6. PubMed ID: 31948451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
    Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
    Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.
    Rodon J; Postel-Vinay S; Hollebecque A; Nuciforo P; Azaro A; Cattan V; Marfai L; Sudey I; Brendel K; Delmas A; Malasse S; Soria JC
    Eur J Cancer; 2017 Aug; 81():142-150. PubMed ID: 28624695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.
    Richardson GE; Al-Rajabi R; Uprety D; Hamid A; Williamson SK; Baranda J; Mamdani H; Lee YL; Nitika ; Li L; Wang X; Dong X
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
    Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
    Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
    Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
    Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
    Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
    Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
    Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
    Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
    Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
    Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
    Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
    Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D
    Invest New Drugs; 2019 Apr; 37(2):271-281. PubMed ID: 30073466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.